$RAPP

Analysts updated ratings for General Dynamics (GD), Rapport Therapeutics (RAPP), and First Solar (FSLR). GD received a Hold rating with a $407 target; consensus is $425.62. RAPP got a Buy rating with a $66 target; consensus is $62.29. FSLR maintained a Buy rating with a $323 target; consensus is $268.25. All targets imply significant upside from current prices.

Rapport Therapeutics (RAPP) shares fell 17.6% after executives discussed clinical plans for RAP-219 at a summit, emphasizing pending Phase 2 data. Analysts maintained bullish ratings but highlighted binary risk. Insider sales and a weak market added to the decline. Shares hit an intraday low of $34.13, nearing the 52-week low of $23.75.

Rapport Therapeutics (RAPP) reached a 52-week high of $52.83. Its lead drug, RAP-219, entered Phase 3 trials for focal onset seizures, with strong clinical data showing sustained seizure reductions. The company reported a Q2 2026 net loss of $56.6M, up from $26.7M a year ago, with cash reserves of $436.1M. RAPP closed at $52.50, up 2.60%.

Five biotech companies reached 52-week highs on August 26, 2026. Cardiol Therapeutics (CRDL) rose 7% to $2.27, reporting a narrower Q2 loss. NeoGenomics (NEO) hit $17.46 after securing Medicare/Medicaid coverage for its RaDaR ST test and reported a Q2 profit. Seaport Therapeutics (SPTX) surged 12% to $28.37 post-IPO, with a wider Q2 loss. Rapport Therapeutics (RAPP) gained 2% to $52.83, advancing its CNS drug candidates. Cullinan Therapeutics (CGEM) reached $23.19, with a narrower Q2 loss and FD

Ceesay Abraham (Chief Executive Officer) sold 18,921 shares of Rapport Therapeutics, Inc. (RAPP) at $49.57 ($0.94M total) on 2026-08-25 under a Rule 10b5-1 trading plan.

Yeleswaram Krishnaswamy (Chief Development Officer) sold 50,160 shares of Rapport Therapeutics, Inc. (RAPP) at an average of $50.47 ($50.00–$51.06, $2.53M total) across 3 trades over 2026-08-24 to 2026-08-25 under a Rule 10b5-1 trading plan.

Ceesay Abraham (Chief Executive Officer) sold 51,499 shares of Rapport Therapeutics, Inc. (RAPP) at an average of $47.25 ($45.97–$48.62, $2.43M total) across 5 trades over 2026-08-10 to 2026-08-11 under a Rule 10b5-1 trading plan.

Rapport Therapeutics, Inc. (RAPP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update RAP-219 Phase 3 program in focal onset seizures initiated, with FOCUS 1 and FOCUS 2 trials enrolling patients RAP-219 Phase 2 trial in bipolar mania on track for topline results

Rapport Therapeutics COO Cheryl Gault sold 10,000 shares of RAPP stock for about $416,000 in open-market trades on June 30, 2026, per an SEC Form 4. The sale reduced her direct holdings by 6.25% to 149,914 shares, worth about $5.9 million. The article notes RAPP shares were up 223.67% year over year as of July 1, 2026.

Rapport Therapeutics, Inc. (RAPP) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0002012593 0002012593 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10,